Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • J&J pharmaceuticals news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J Business: Pharmaceuticals Johnson & Johnsons Janssen Pharmaceutica N.V. and Johnson & Johnson Innovation units launched European incubator JLINX with undisclosed venture …

    Published on 3/21/2016
  • Opexa autoimmune news

    Opexa Therapeutics Inc. (NASDAQ:OPXA), The Woodlands, Texas Business: Autoimmune Opexa reduced headcount by 10 (28%) to 26 to conserve cash and focus resources on completing the Phase IIb Abili-T trial of Tcelna …

    Published on 3/21/2016
  • Telesta cancer news

    Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF), Belleville, Ontario Business: Cancer Telesta reduced headcount by about 9 (15%) to about 50 to conserve cash while it conducts a full review of strategic options over …

    Published on 3/21/2016
  • Aegerion, Hayman Capital Management endocrine/metabolic news

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Hayman Capital Management, Dallas, Texas Business: Endocrine/Metabolic The U.S. Patent Trial and Appeal Board instituted two inter partes review petitions …

    Published on 3/14/2016
  • Amarin endocrine/metabolic news

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Endocrine/Metabolic FDA agreed to be bound by the Aug. 7, 2015, preliminary injunction by the U.S. District Court for the Southern District of New York allowing …

    Published on 3/14/2016
  • Amgen, Novartis autoimmune, biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Autoimmune, Biosimilars Amgen filed suit against Novartis Sandoz unit in the U.S. District Court for the …

    Published on 3/14/2016
  • Biogen autoimmune news

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Autoimmune The European Patent Office (EPO) revoked Biogens European Patent No. EP2137537 covering treatment of multiple sclerosis (MS) with 480 mg Tecfidera …

    Published on 3/14/2016
  • Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

    Crescita Therapeutics Inc. (TSX:CTX), Mississauga, Ontario Nuvo Pharmaceuticals Inc. (TSX:NRI), Mississauga, Ontario Business: Drug delivery, Inflammation, Neurology Nuvo Pharmaceuticals (formerly Nuvo Research Inc.) …

    Published on 3/14/2016
  • Eli Lilly, Indiana Biosciences Research Institute endocrine/metabolic news

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Indiana Biosciences Research Institute, Indianapolis, Ind. Business: Endocrine/Metabolic The not-for-profit institute received two grants totaling $100 million to support…

    Published on 3/14/2016
  • Foundation Medicine cancer news

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Business: Cancer Foundation Medicine will release to the public molecular profiles of pediatric cancers from its FoundationCORE database to stimulate and …

    Published on 3/14/2016
  • Ignyta cancer news

    Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Business: Cancer Ignyta ceased development of preclinical cancer programs RXDX-103, RXDX-107 and RXDX-108 to focus on its molecularly targeted pipeline and reduce operating …

    Published on 3/14/2016
  • J&J cancer news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Johnson & Johnson launched a JLABS incubator in Houston, Texas. The facility is housed within the Texas Medical Center (TMC) Innovation Institute. J&J …

    Published on 3/14/2016
  • NephroGenex renal news

    NephroGenex Inc. (NASDAQ:NRX), Research Triangle Park, N.C. Business: Renal NephroGenex halted clinical development of oral Pyridorin pyridoxamine to treat diabetic nephropathy in light of the remaining trial costs, the…

    Published on 3/14/2016
  • True North Therapeutics hematology news

    True North Therapeutics Inc., South San Francisco, Calif. Business: Hematology True North launched COMPASS, a patient registry for patients with cold agglutinin disease (CAD), a rare type of autoimmune hemolytic anemia.…

    Published on 3/14/2016
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Earlier this month, Novartis Sandoz unit asked the U.S. Supreme Court to review a lower courts…

    Published on 2/29/2016
  • Caribou Biosciences genomics news

    Caribou Biosciences Inc., Berkeley, Calif. Business: Genomics The U.S. Patent and Trademark Office (USPTO) granted Caribou U.S. Patent No. 9,260,752, which describes compositions and methods of using CRISPR to detect …

    Published on 2/29/2016
  • Illumina, Oxford Nanopore genomics news

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Oxford Nanopore Technologies Ltd., Oxford, U.K. Business: Genomics Illumina filed two concurrent lawsuits against Oxford Nanopore alleging that the nanopore-based …

    Published on 2/29/2016
  • Juno Therapeutics, Fred Hutchinson, Seattle Cancer Care Alliance, University of Washington cancer news

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Fred Hutchinson Cancer Research Center, Seattle, Wash. Seattle Cancer Care Alliance (SCCA), Seattle, Wash. University of Washington, Seattle, Wash. Business: Cancer …

    Published on 2/29/2016
  • Pfizer gastrointestinal news

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Gastrointestinal Pfizer will pay $784.6 million to resolve allegations regarding Medicaid rebate claims for its gastrointestinal drug Protonix pantoprazole, a proton …

    Published on 2/29/2016
  • Allergan, Eli Lilly cancer news

    Allergan plc (NYSE:AGN), Dublin, Ireland Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K. High Court ruled that Eli Lillys Alimta pemetrexed vitamin dosing regimen patent would not be infringed…

    Published on 2/22/2016
  • Collegium, Purdue Pharma neurology news

    Collegium Pharmaceutical Inc. (NASDAQ:COLL), Canton, Mass. Purdue Pharma L.P., Stamford, Conn. Business: Neurology A judge in the District Court of Massachusetts issued an order for final judgment dismissing Purdues …

    Published on 2/22/2016
  • GlaxoSmithKline, Competition and Markets Authority neurology, generics news

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Competition and Markets Authority (CMA), London, U.K. Business: Neurology, Generics CMA imposed L45 million ($64.8 million) in fines for pay-for-delay conduct and …

    Published on 2/22/2016
  • Aegerion endocrine/metabolic news

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Business: Endocrine/Metabolic Aegerion will reduce global staff by about 77 (25%) to about 230 to cut costs as its hypercholesterolemia treatment Juxtapid …

    Published on 2/15/2016
  • Biodel endocrine/metabolic news

    Biodel Inc. (NASDAQ:BIOD), Danbury, Conn. Business: Endocrine/Metabolic In January, Biodel reduced headcount by 15 non-executive employees to preserve cash. The company expects to reduce average operating cash burn to …

    Published on 2/15/2016
  • Biogen functional genomics news

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Functional genomics Biogen joined the Centre for Therapeutic Target Validation (CTTV), which is using genome sequencing and big data tools to research drug targets. …

    Published on 2/15/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993